{"text": "Therefore, the AKT inhibitor perifosine might potentially overcome the resistance to cisplatin-based chemotherapy in NSCLC patients with low-FHIT tumors, and consequently improve the outcome.", "denotations": [{"id": "T1", "obj": "gene", "span": {"begin": 15, "end": 18}}, {"id": "T2", "obj": "disease", "span": {"begin": 117, "end": 131}}, {"id": "T3", "obj": "disease", "span": {"begin": 137, "end": 152}}]}
